Gael LHeveder - PCI Biotech Chief Bus. Devel. Officer
| PCIB Stock | NOK 1.72 0.02 1.18% |
Executive
Mr. Gael LHeveder no longer serves as Chief Business Development Officer at PCI Biotech Holding ASA, effective as of the end of March 2019 . He has held the position since April 8, 2013. He holds a MS in Bioorganic Chemistry from Universite Louis Pasteur, Strasbourg, France. He has more than 20 years experience and an extensive network in international pharmaceutical industry through various positions in Aventis, Baxter and Roche. This includes more than 10 years in business development functions, particularly in market intelligence and licensing. Before his current position in PCI Biotech, he held the position as Partnering Director leading clinicalstage licensing transactions for Roche in Basel, Switzerland. since 2013.
| Age | 50 |
| Tenure | 11 years |
| Phone | (47) 67 11 54 00 |
| Web | www.pcibiotech.com |
PCI Biotech Management Efficiency
The company has return on total asset (ROA) of (0.3973) % which means that it has lost $0.3973 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.7359) %, meaning that it generated substantial loss on money invested by shareholders. PCI Biotech's management efficiency ratios could be used to measure how well PCI Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Rune Helland | DnB ASA | 57 | |
| Siri Berge | Telenor ASA | N/A | |
| Arild Frick | Aker ASA | 38 | |
| Jan Gjerland | DnB ASA | N/A | |
| Kristian Rokke | Aker ASA | 36 | |
| Hakon Kjol | Telenor ASA | 45 | |
| Aud Skrudland | Sparebank 1 SMN | 57 | |
| Baard Snekkevik | Aker ASA | 52 | |
| Ola Nerasen | Sparebank 1 SMN | 58 | |
| Odd Grefstad | Storebrand ASA | 58 | |
| Paul HjelmHansen | Sparebank 1 SMN | 54 | |
| Marit Solberg | Sparebanken Vest | 59 | |
| Gunn Waersted | Telenor ASA | 64 | |
| Ragnhild Fresvik | Sparebanken Vest | 38 | |
| Marianne Stigset | Aker ASA | N/A | |
| Arnhild Holstad | Sparebank 1 SMN | 53 | |
| Stig Vangen | Sparebanken Vest | N/A | |
| Marianne Moe | Telenor ASA | N/A | |
| Jorgen Kildahl | Telenor ASA | 56 | |
| Robin Kamark | Storebrand ASA | 52 | |
| Atle Kigen | Aker ASA | 65 | |
Management Performance
| Return On Equity | -0.74 | |||
| Return On Asset | -0.4 |
PCI Biotech Holding Leadership Team
Elected by the shareholders, the PCI Biotech's board of directors comprises two types of representatives: PCI Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PCI. The board's role is to monitor PCI Biotech's management team and ensure that shareholders' interests are well served. PCI Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PCI Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lucy Wabakken, Acting CDO | ||
| Per Walday, CEO | ||
| Erling Overland, Chairman of the Board | ||
| Anders Hogset, Chief Scientific Officer | ||
| Hans Bohn, Director | ||
| Kristin Eivindvik, Chief Officer | ||
| Hans Olivecrona, Chief Medical Officer | ||
| Hilde Furberg, Director | ||
| Kjetil Tasken, Director | ||
| Gael LHeveder, Chief Bus. Devel. Officer | ||
| Anders Hgset, Chief Officer | ||
| Lars Viksmoen, Director | ||
| Andrew Hughes, Director | ||
| Ronny Skuggedal, CEO CFO | ||
| Hilde Steineger, Director | ||
| Christina Herder, Director |
PCI Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PCI Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.74 | |||
| Return On Asset | -0.4 | |||
| Operating Margin | (15.29) % | |||
| Current Valuation | 25.47 M | |||
| Shares Outstanding | 37.33 M | |||
| Shares Owned By Insiders | 31.97 % | |||
| Shares Owned By Institutions | 6.90 % | |||
| Price To Earning | (10.88) X | |||
| Price To Book | 1.44 X | |||
| Price To Sales | 18.74 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards PCI Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, PCI Biotech's short interest history, or implied volatility extrapolated from PCI Biotech options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as PCI Biotech Holding using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PCI Biotech Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Complementary Tools for PCI Stock analysis
When running PCI Biotech's price analysis, check to measure PCI Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PCI Biotech is operating at the current time. Most of PCI Biotech's value examination focuses on studying past and present price action to predict the probability of PCI Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PCI Biotech's price. Additionally, you may evaluate how the addition of PCI Biotech to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Stocks Directory Find actively traded stocks across global markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |